Biocon gets DCGI nod to use Itolizumab in moderate to severe Covid-19 patients

Biocon said the approval is based on the results from the successful conclusion of a randomized, controlled clinical trial at multiple hospitals in Mumbai and New Delhi. The drug inhibits the production of pro-inflammatory cytokines, proteins released by cells. Cytokine storm is a complication of Covid-19.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3iOdZGZ
via IFTTT